Editor's Note: Tired of watching the markets whipsaw and not knowing what to trade? "Market Wizard" Larry Benedict says most traders are doing too much – too many tickers, too many indicators, too many decisions. His approach? One ticker. One trade in the morning. Done by 4 p.m. He's mapped out a brand-new calendar of pre-determined weekly profit opportunities for 2026... and the next one opens in the next few days. See below...
Dear Reader,
If you're tired of watching dozens of tickers, stressing over indicators, and still not knowing what to trade...
Trading legend Larry Benedict has a better way.
He's discovered a predictable, repeatable pattern...
Hidden inside the AI chaos that's been rocking the markets almost every week.
He's mapped every opportunity on what he calls his AI Chaos-to-Cash Calendar.
Handing anyone armed with Larry's simple system...
A chance to collect a full-time income trading just a few hours a month...
Using just ONE ticker over and over again.
Week after week, like clockwork.
No watching screens all day. No complicated analysis. No guessing which direction the market is heading.
Just one trade with your morning coffee... go about your day... and if your trade goes your way, you're pocketing hundreds or even thousands by 4 p.m. ET.
And the best part is...
EVERY single one of these opportunities is pre-determined months in advance. Some by federal mandate.
Which makes this as predictable as anything Larry says he's seen in his 40-year career.
If you'd like to see how it's done before the next “AI Chaos-to-Cash" opportunity opens...
Join Larry for an exclusive event THIS THURSDAY.
(When you click the link, your email address will automatically be added to Larry’s guest list.)
You'll see exactly how Larry's system works step-by-step...
You'll get the name of the ONE ticker you need to trade...
And Larry's showing you his AI Chaos-to-Cash Calendar of pre-determined weekly profit opportunities filled in and ready to go.
HURRY. The next opportunity is opening up in just a few days...
Click here to save your seat for THIS THURSDAY, March 26, at 2 p.m. ET sharp.
Regards,
Lauren Wingfield
Managing Editor, The Opportunistic Trader
P.S. You're getting the same ONE ticker and trading setup Larry used to generate $274 million in profits for his private clients... and profit $8 million in ONE day.
Click here to reserve your spot now to avoid missing out.
Trade Desk Pops on Possible OpenAI Deal—Game Changer or Headfake?
Authored by Leo Miller. Article Published: 3/10/2026.
Key Points
- Trade Desk shares have taken a huge hit, trading at some of their lowest levels in recent memory.
- However, the stock received new life after reports emerged of a potential advertising deal with ChatGPT maker OpenAI.
- Could this possible deal change TTD's fortunes, or should investors continue to exercise caution around this stock?
- Special Report: The Biggest IPO Ever: Claim Your Stake Today
Advertising technology stock The Trade Desk (NASDAQ: TTD) has underperformed recently, with shares down more than 50% over the past 52 weeks.
That trend paused on March 5, when shares surged more than 18% after reports that The Trade Desk is in talks with OpenAI to help place advertisements in ChatGPT. The discussions are reportedly in the early stages.
5 American Billionaires Dumping Dollars (Ad)
Zuckerberg... Musk... Ellison... Brin... Page...
When the people with the best information about where the economy is going choose another type of currency over dollars, you sit up and take notice.
47-year market veteran Louis Navellier has documented the pattern - and identified the key steps you should take right now.
See What He FoundThe excitement is understandable: ChatGPT now has 900 million weekly active users. If Trade Desk became one of OpenAI's key partners, a substantial amount of advertising spend could flow through its platform.
Here's what that potential partnership would mean — and how much it might change the picture for TTD stock.
ChatGPT: TTD's LLM advertising opportunity
Markets have growing concerns about OpenAI's ability to generate revenue that consistently exceeds costs, so the company is exploring additional revenue streams.
One of the key initiatives is placing ads on ChatGPT. In January, OpenAI said it plans to begin testing ads in the United States on its free and Go tiers. The Plus, Pro, Business, and Enterprise tiers will not include ads.
For Trade Desk, this represents a meaningful opportunity. Trade Desk provides platforms that companies use to buy and manage ads; when advertisers place ads through TTD's systems, the company takes a percentage of that ad spend. If OpenAI routes ad buying through Trade Desk, TTD could capture a share of ChatGPT-driven ad dollars.
The potential is amplified by how ChatGPT's user base is structured. Reports suggest that as of July 2025, only about 5% of OpenAI's users were on its Plus or Pro tiers. OpenAI also reported in November 2025 that it had seven million ChatGPT for Work seats. The figures are approximate, but they indicate the vast majority of users are on the free and Go tiers — where ads could appear.
That scale could let Trade Desk facilitate ad buying across a large portion of ChatGPT's audience.
Criteo, Perplexity, and the early days of LLM advertising
Adding credibility to the chatter is OpenAI's existing partnership with a smaller ad-tech firm: Criteo (NASDAQ: CRTO). Criteo is OpenAI's first advertising technology partner, and some early results look encouraging.
Criteo reports that referrals from LLMs like ChatGPT convert at roughly 1.5 times the rate of other channels, meaning advertisers may get more qualified interest from LLM-driven referrals — a powerful incentive to use the channel.
That said, Criteo is much smaller than Trade Desk. Criteo says it activates over $4 billion in ad spending annually, compared with roughly $13.4 billion in gross spending routed through Trade Desk's platform in 2025. It's possible OpenAI is piloting with Criteo and could expand to larger partners like Trade Desk if the model scales.
There are also reasons to be cautious. AI search tool Perplexity recently reversed course on ads, citing concerns that ads could erode consumer trust. That highlights a real risk for LLM advertising: user trust and engagement may be sensitive to ad insertion.
Still, ChatGPT's sheer user base gives it an advantage. Perplexity attracts a user base in the "tens of millions," a fraction of ChatGPT's hundreds of millions. Larger audiences improve ad targeting and make the platform more attractive to advertisers. Additionally, Perplexity is shifting toward enterprise use, while OpenAI is pursuing both consumer and enterprise customers — increasing the odds OpenAI will continue experimenting with ads.
TTD: beaten-down stock facing significant uncertainty
At current levels, TTD's valuation implies long-term growth well below its historical rates. That may be partly justified: revenue rose just 14% last quarter, the company's slowest growth in more than five years and a noticeable drop from 22% growth in Q4 2024. Still, the market may be overly pessimistic about TTD's upside if an OpenAI relationship materializes.
The consensus price target on TTD sits near $43, implying roughly 50% upside from current levels. Targets updated after the company's most recent earnings averaged around $34, implying closer to 15–20% upside from the stock's current price near $29. Analysts' estimates vary widely, ranging from $17 to $55. Overall, despite the OpenAI potential, substantial uncertainty remains around Trade Desk's future.
Patience Pays: Hims & Hers Surges on News of Novo Nordisk Deal
Submitted by Jordan Chussler. Publication Date: 3/10/2026.
Key Points
- Hims & Hers has shifted from offering controversial compounded GLP-1s to a formal agreement with Novo Nordisk, allowing the platform to distribute FDA-approved Ozempic and Wegovy.
- Following the announcement, HIMS shares surged nearly 46%, helping the stock recover from a 59% drop earlier in the year caused by previous legal friction with Novo Nordisk.
- Analysts have upgraded the stock, citing the partnership as a major growth catalyst; despite a year-to-date loss, earnings are projected to grow by over 79% next year.
- Special Report: The Biggest IPO Ever: Claim Your Stake Today
After falling 59% from its year-to-date high, embattled healthcare stock Hims & Hers Health (NYSE: HIMS) is drawing attention as shares surge following an agreement with GLP-1 maker Novo Nordisk (NYSE: NVO)—the same company that filed a patent infringement lawsuit against Hims & Hers on Feb. 9.
After withdrawing its compounded semaglutide offering that was modeled after Novo Nordisk's weight-loss drugs, Wegovy and Ozempic, Hims & Hers said in a press release that the two firms have entered a strategic partnership that will make Novo Nordisk's branded GLP-1 drugs available through Hims & Hers' telehealth platform.
5 American Billionaires Dumping Dollars (Ad)
Zuckerberg... Musk... Ellison... Brin... Page...
When the people with the best information about where the economy is going choose another type of currency over dollars, you sit up and take notice.
47-year market veteran Louis Navellier has documented the pattern - and identified the key steps you should take right now.
See What He FoundSince the announcement, HIMS has gained nearly 46% and received analyst upgrades as Wall Street turns more bullish on the direct-to-consumer prescription drug provider.
A Strategic Shift From Compounded GLP-1 to FDA-Approved Drugs
Compounded GLP-1 alternatives emerged to fill demand amid shortages of approved weight-loss drugs, but those compounds lack U.S. Food and Drug Administration (FDA) approval.
While they increased access to lower-cost substitutes for brand-name medicines such as Ozempic and Wegovy and often used similar active ingredients (for example, semaglutide and tirzepatide, the latter marketed as Mounjaro and Zepbound), the absence of FDA review means these alternatives did not undergo formal quality and efficacy evaluations. That increases the risk of incorrect dosages, improper storage and other safety issues.
According to Hims & Hers' press release, as part of the company's shift away from compounded GLP-1 offerings, "existing patients will have the opportunity to transition to FDA-approved medicines."
Specifically, "Hims & Hers has entered into an agreement with Novo Nordisk that will bring Ozempic (semaglutide) 0.5 mg, 1 mg, and 2 mg injections and Wegovy (semaglutide) pills and injections to the platform later this month, including 1.7 mg or 2.4 mg injections and 1.5 mg, 4 mg, 9 mg, and 25 mg tablets."
Co-founder and CEO Andrew Dudum said the deal should create "tremendous growth opportunities in the U.S. with the expanding assortment of branded GLP-1 medications." He added that the "collaboration reflects what's possible globally when drugmakers, biotech companies, and diagnostic leaders partner with consumer platforms to support scaled distribution of their latest medical innovations."
Shares of HIMS Are Still Struggling, But the Future Looks Promising
The news and the sizable jump in the stock price were welcomed by shareholders who have endured Hims & Hers' volatility over the past year. Even after the February sell-off tied to the Novo Nordisk lawsuit, analysts have remained generally bullish; some 12-month price targets implied as much as 150% potential upside.
Despite the March 9 surge, HIMS shares are still down about 33% over the last 12 months. On the fundamentals, however, Hims & Hers appears positioned to sustain momentum.
When the company reported full-year and Q4 2025 results on Feb. 23, it posted an earnings-per-share (EPS) beat and a slight revenue miss. EPS of $0.08 topped analyst expectations of $0.02, while revenue of $617.82 million fell just short of the $619.48 million analysts expected.
It was the company's first EPS beat since the first quarter of last year. More importantly, the financials showed steady, sustainable revenue growth, with a three-year average of 64.60%. While earnings contracted in 2025, that followed EPS growth of nearly 582% in 2024 and roughly 66% in 2023.
Hims & Hers Health's earnings are forecast to grow about 79.31% next year, from $0.29 per share to $0.52 per share.
HIMS Receives Analyst Upgrades as Wall Street Turns Bullish on Telehealth
After the Novo Nordisk announcement, Bank of America Securities upgraded HIMS to Neutral from Underperform and raised its price target to $23 from $12.50.
Notably, the firm's prior price target excluded contributions from GLP-1 revenue, underscoring how the agreement with Novo Nordisk is being viewed as a meaningful catalyst by Wall Street.
Overall, HIMS carries a consensus Hold rating from 17 analysts covering the stock. The average one-year price target implies roughly 32% upside.
Current short interest of 43.24% of the shares outstanding should be watched; that level—about $1.32 billion worth of shares—is substantially lower than the approximately $4.27 billion that were shorted last July. That downtrend has continued, and it would not be surprising to see institutional buyers increase their exposure in coming quarters as the Novo Nordisk deal supports Hims & Hers' top-line growth.
to bring you the latest market-moving news.
This email message is a paid advertisement provided by Brownstone Research, a third-party advertiser of TickerReport and MarketBeat.
Contact Us | Unsubscribe
© 2006-2026 MarketBeat Media, LLC dba TickerReport. All rights reserved.
345 North Reid Place, Suite 620, Sioux Falls, South Dakota 57103. United States of America..
0 Response to "Turns chaos into cash"
Post a Comment